Cancer Immunology and Immunotherapy Program

大卫F.和玛格丽特T。Grohne家族癌的免疫学和免疫治疗 项目概要 癌症免疫学和免疫治疗（CII）计划是一个长期的基础和转化科学 在马约诊所癌症中心（MCCC）的计划。2016年，该计划正式由 大卫F.和玛格丽特·T. Grohne家族该计划继续努力，以更好地了解 免疫机制，炎症和癌症之间的关系，以及 通过免疫疗法对抗癌症的创新解决方案。CII计划做出了重大贡献 检查点阻断疗法，这导致了几个国家的护理标准发生了重大变化。 不同的癌症它现在准备做出更多的重大贡献，例如使用抗体靶向 化疗药物，有效地针对黑色素瘤和卵巢癌，这已被证明是无反应的 已建立的疗法。该方案包括35名成员，代表马约的14个不同部门 临床医学与科学学院。目前的成员是一个历史上高生产力的团队， 发表论文超过5000篇，被引用次数超过245，000次。的主要目标 该计划旨在提供一个互动的、支持性的和持久的科学环境，以培养我们的四个 主要尖端具体目标：（1）开发关于免疫系统如何运作的新知识， (2)开发新的基于抗体的癌症治疗方法（3）鉴定和开发疫苗 可以实施的方法，以防止癌症复发和提高免疫治疗的功效， 调节与检查点抑制剂，和（4）开发创新的策略，以重定向非肿瘤抗原- 特异性T细胞攻击癌症。CII计划一直资金充足，目前得到支持 由校外同行评审的赠款总额为360万美元的直接成本，其中约35%来自NCI。直接供资 来自非同行评审赠款的资金为840万美元，总计1200万美元。这是一个20%的增长， 最后一次融资。在2013-2017年期间，项目成员发表了650篇与癌症相关的出版物， 其中19%是计划内的，57%是跨计划的，124篇发表在期刊上， 影响因子≥10，反映工作质量，说明CII的交互程度高 计划成员与其他MCCC计划的成员有联系。

DAVID F. AND MARGARET T. GROHNE FAMILY CANCER IMMUNOLOGY AND IMMUNOTHERAPY PROGRAM PROJECT SUMMARY The Cancer Immunology and Immunotherapy (CII) Program is a longstanding basic and translational sciences program within the Mayo Clinic Cancer Center (MCCC). In 2016, this program was officially endowed by the David F. and Margaret T. Grohne Family. The Program continues to work toward better understanding the mechanisms of immunity, the relationship between inflammation and cancer, and the development of innovative solutions to combat cancer through immune therapy. The CII Program has contributed significantly to checkpoint blockade therapy, which has resulted in a major change in the standard of care of several different cancers. It is now poised to make additional major contributions such as using antibody-targeted chemotherapeutics, effectively targeting melanoma and ovarian cancers, which have proven nonresponsive to established therapies. The Program includes 35 members, representing 14 different departments in the Mayo Clinic College of Medicine and Science. The current membership is a historically highly productive team with a total publication record in excess of 5000 papers that has garnered over 245,000 citations. The main goal of the Program is to provide an interactive, supportive, and durable scientific environment to foster our four principal cutting-edge Specific Aims: (1) To develop new knowledge about how the immune system functions, (2) To develop novel antibody-based therapies for the treatment of cancers (3) To identify and develop vaccine approaches that can be implemented to protect against cancer recurrence and improve the efficacy of immune modulation with checkpoint inhibitors, and (4) To develop innovative strategies to redirect non-tumor antigen- specific T cells to attack cancer. The CII Program has been consistently well-funded and currently is supported by extramural peer-reviewed grants totaling $3.6M in direct costs of which ~35% are from NCI. Direct funding from non-peer-reviewed grants is $8.4M resulting in an overall total of $12M. This is a 20% increase over the last funding period. In the 2013-2017 timeframe, Program members published 650 cancer-related publications, of which 19% were intraprogrammatic, 57% were interprogrammatic, and 124 were published in journals with impact factors ≥10, reflecting the quality of the work and illustrating the high degree of interaction the CII Program members have with members of other MCCC Programs.